172 related articles for article (PubMed ID: 17518123)
1. Managing anemia: what do we do now?
Neumann ME
Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
[No Abstract] [Full Text] [Related]
2. The FDA, stocks, black boxes and ESAs.
Spry L
Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124
[No Abstract] [Full Text] [Related]
3. Reaction from renal associations. Renal Physicians Association.
Blaser R
Nephrol News Issues; 2007 May; 21(6):61-2, 64. PubMed ID: 17518126
[No Abstract] [Full Text] [Related]
4. The FDA black box for EPO: what should nephrologists do?
Singh AK
Nephrol News Issues; 2007 May; 21(6):55-6, 58-9. PubMed ID: 17518125
[No Abstract] [Full Text] [Related]
5. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
6. Reimbursement for erythropoiesis-stimulating agents poses challenges.
Traynor K
Am J Health Syst Pharm; 2008 Mar; 65(5):385-6. PubMed ID: 18281727
[No Abstract] [Full Text] [Related]
7. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
8. Safety concerns for two big anemia drugs.
Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
[No Abstract] [Full Text] [Related]
9. Biosimilar epoetins.
Macdougall IC
Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
[No Abstract] [Full Text] [Related]
10. Erythropoietins should be used according to guidelines.
Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
[No Abstract] [Full Text] [Related]
11. Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin.
McKoy JM; Tigue CC; Bennett CL
Cancer Treat Res; 2008; 140():235-51. PubMed ID: 18283779
[No Abstract] [Full Text] [Related]
12. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
13. Erythropoietin claims monitoring policy: implications for clinical practice.
Messana T
Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
[TBL] [Abstract][Full Text] [Related]
14. Finding a rational approach to ESA therapy--for payers and patients.
Messana A
Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
[No Abstract] [Full Text] [Related]
15. [Recent advances on the use of erythropoietin in oncology].
Spaëth D
Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan.
Nakagawa T
Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854
[No Abstract] [Full Text] [Related]
17. Darbepoetin alfa and chronic kidney disease.
Hampl H; Kovesdy CP; Kalantar-Zadeh K
N Engl J Med; 2010 Feb; 362(7):654; author reply 655. PubMed ID: 20187260
[No Abstract] [Full Text] [Related]
18. A star rises, another fades.
Neumann ME
Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618
[No Abstract] [Full Text] [Related]
19. New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka M
JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
[No Abstract] [Full Text] [Related]
20. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
[Next] [New Search]